Author of

• 25952

  +

  P2.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 964)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 27898

    +

    P2.15-02 - Gender-Associated Differences in Patients with Lung Cancer Treated at an Argentinean University Hospital in the Last 10 Years  (ID 12207)

    16:45 - 18:00  |  Author(s): Mauricio Tournour
    • Abstract
    • Slides

    Background
    

    In the last 20 years, lung cancer became in the first cause of death worldwide among women and is responsible for 20,000 deaths yearly in Argentinean women. Retrospective data suggest differences in incidence and outcome according to gender. We report the clinicopathologic profile and outcome of lung cancer patients assisted in our institution in the last decade according to gender.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    We retrospectively, relieved the female population with lung cancer with available data treated at Institute of oncology Angel H. Roffo in the last 10 years to compare their clinical, pathological and epidemiologic variables such as: age, gender, histology ,molecular testing (EGFR mutations, ALK rearrangement), PET-TC at diagnosis ,stage, ECOG, PS and weight loss, with a cohort of male patients in the same period of time and their outcome (OS)..

    4c3880bb027f159e801041b1021e88e8 Result
    

    From a total of 395 charts reviewed, 180 (45.6%) women and 215 (54.4%) men shared no differences in the median age of lung cancer diagnosis; 62 (30-92) and 63 (28-84) year, respectively (p=0,16). Differing from men, more women come from Buenos Aires urban and suburban areas (89 vs 79%) (p=0,003). Compared to men, women had a lower incidence of: SCC (squamous cell carcinoma) (24/180, 13% vs 38/215, 18%)(p=0,020), advanced disease (stage III-IV)(136/180, 75% vs 190/215 88%)(p=0,001), smoking history (126/180, 70% vs 203/215, 94%)(p=0,000), consumption of tobacco (Mean 24 pack/year ±30 vs 41±33) (p=0,000)and presence of symptoms at diagnosis (141/180, 78% vs 193/215, 90%)(p=0,006). At the molecular level, women had more positive EGFRm cases (28, 15% vs 13 6%) (p=0,008) than men. Overall, median survival was superior for women (24 months; IC95%, 20-28 vs 20 months; IC95% 15-24) (p=0,15), especially in stage IV disease, but it was not statistically significant.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Our data confirms gender-associated differences in the clinical and pathologic profile of lung cancer in an Argentinean cohort of patients. Although not statistically significant, women would also had a better outcome than men. This analysis represents the first step of a prospective project to determine the clinic, epidemiological and molecular characteristics related to gender in lung cancer in our population

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.